

HIT Supplement 2: Disclosure of Interests Forms of the Guideline Panel

Gowthami Arepally

Beng Chong

Douglas Cines

Adam Cuker

Andreas Greinacher

Yves Gruel

Lori Linkins

Stephen Rodner

Nancy Santesso

Sixten Selleng

Ted Warkentin

Ashleigh Wex



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>
Biokit	Exclusive license for monoclonal antibody	Ongoing	The antibody is licensed to Biokit and used for HIT testing.

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
UNM-STC	Patent and license holder for KKO monoclonal antibody; they disburse earnings from Biokit	Ongoing	As noted above, the antibody is licensed to Bio-kit and used for HIT testing.

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
TEVA	Research support for studies	PI	ongoing	Not an affected company. Teva has no branded anticoagulant products or assays. The company does make hundreds of generic pharmaceutical products.
Quantimmune	Research support for reagents	PI	ongoing	Quantimmune is a small company that has developed potency assays for biologics. To our knowledge, the company is not possibly affected by guidelines on HIT.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Heparin-Induced Thrombocytopenia

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Complete support

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Hematology

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain: I recommend diagnostic testing as well as treatment for VTE/PE and HIT

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Heparin-Induced Thrombocytopenia
----------------------------	---

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Reviewer and date</i>	<i>Notes</i>
Yes	Conflicted minority	Yes	4/9/15; 4/25/15	In addition to her material interest with Bio-kit, Dr. Arepally is the PI for research supported by TEVA and Quantimmune.
Yes	Conflicted minority	Yes	10/13/16 Alexander; 10/26/16 Kunkle	New financial interests disclosed. See Part D.
Yes	Conflicted minority	Yes	7/31/18 Alexander	Updates to disclosures. See Part D. On 6/22/2018 Dr. Arepally confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Biokit	Exclusive license for monoclonal antibody	4/09/15	The antibody is licensed to Biokit and used for HIT testing. Earnings are disbursed by UNM-STC.
Momenta Pharmaceuticals	Direct payment for consulting	9/23/16	COI. Momenta markets enoxaparin.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Apotex Inc.	Direct payment for consulting	9/23/16	COI. Apotex markets enoxaparin.

Notes:

--

Part D. New Declarations

The following interests were disclosed after appointment:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Momenta Pharmaceuticals	Direct payment for consulting	9/23/16	COI. Momenta markets enoxaparin.
Apotex Inc.	Direct payment for consulting	9/23/16	COI. Apotex markets enoxaparin.
TEVA	Research support for studies. This activity ended in 2014.	6/22/2018	This is an update to Part A, Question 4.



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Amgen	Title: A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of ITP . <i>Funding goes to institution (St George Hospital)</i>	A site investigator. A co-author of ASH 2014 meeting poster and an on-coming manuscript	14 July 2014	Ended before appointment
Amgen	Multicentre, international, prospective, observational study of subjects with RR- Multiple Myeloma , who are starting the regimen of lenalidomide with dexamethasone. <i>Funding goes to institution (St George Hospital)</i>	A site investigator	6 Nov 2013	Ended before appointment
Incyte	A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 to Subjects with Primary Myelofibrosis (PMF) , Post-Polycythemia Vera- Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis. In Nov 2012, the above rolled over to: An Open-Label, Multiple Simon 2-Stage Study of INCB039110 Administered Orally to Subjects With Primary Myelofibrosis (PMF) , Post Polycythemia Vera-Myelofibrosis (PPVMF) or Post Essential Thrombocythemia-Myelofibrosis (PET-MF) <i>Funding goes to the institution (St George Hospital)</i>	A site investigator. <i>My involvement with this study ceased the death of my patient in Mar 2015.</i>	Mar 2015	Ended before appointment

Company	Description of Research	My Role	End Date	For ASH Internal Use
GSK	<p>A Multi-centre, prospective disease registry for adults diagnosed with primary immune thrombocytopenia (ITP) in international countries.</p> <p><i>Funding goes to the institution (St George Hospital)</i></p>	<p>Chair of steering committee.</p> <p>This registry may terminate in July 2015 with reorganization within GSK</p>	Probably July 2015	<p>No COI. GSK is an affected company (fondaparinux and argatroban), and Dr. Chong has a leadership role for this registry. However, all funding has gone to his institution, and the research is not related to HIT.</p>
Bayer	<p>Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus ASA in the longterm prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism</p> <p><i>Funding goes to the institution (St George Hospital)</i></p>	<p>Site investigator.</p> <p><i>If ASH deems that there is a problem with me continuing as a site investigator, I will hand over the investigator role to a colleague.</i></p>	On-going	<p>No COI. Although Bayer is an affected company, Dr. Chong does not have a leadership role for this study and all funding goes to his institution.</p>
Alexion	<p>A global, observational, non-interventional study collecting effectiveness, safety and quality of life data on patients with Paroxysmal Nocturnal Haemoglobinuria (PNH) Disease.</p> <p><i>Funding goes to the institution (St George Hospital)</i></p>	<p>Site investigator.</p> <p><i>If ASH deems that there is a problem with me continuing as a site investigator, I will hand over the investigator role to a colleague.</i></p>	On-going	<p>Alexion has no products that would be affected by guidelines on HIT.</p>

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
GSK	A randomised, single blinded, placebo-controlled, dose finding study to assess the PK interaction, safety and efficacy of the oral thrombopoietin receptor agonist, eltrombopag, administered to subjects with Acute Myelogenous Leukaemia (AML) receiving induction chemotherapy <i>Funding goes to the institution (St George Hospital)</i>	Site investigator	Nov 2016	No COI. Although GSK is an affected company, Dr. Chong does not have a leadership role for this study, all funding goes to his institution, and the study is not related to VTE.
EISEI	A Phase 3, Multicentre, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Plus Standard of care for the treatment of ITP <i>Funding goes to the institution (St George Hospital)</i>	Site investigator	June 2013	Ended before appointment

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Heparin-Induced Thrombocytopenia (HIT)

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Invited Reviews/ commentaries:

1. **Chong BH**, Chong JJ. HIT: nucleic acid masquerading as heparin. *Blood*. 2013; Jul 11; 122(2):156-8.
2. Warkentin TE, Greinacher A, Gruel Y, Aster RH, **Chong BH**. On behalf of the Scientific and standardization committee communications. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis of HIT. *J Thromb Haemost*. 2011; 9 (12); 2498-2500.

3. **Chong BH**, JH Chong. Heparin-induced thrombocytopenia associated with fondaparinux. *Clinical Advances in Hematology and Oncology*. 2010; 8(1): 63-65.
4. Shantsila E, Lip GYH, **Chong BH**. Heparin-induced thrombocytopenia: A Contemporary clinical approach to diagnosis and management. *Chest*. 2009. 135:1651-64.
5. **Chong BH**, Isaacs, A. Heparin-induced Thrombocytopenia: What clinicians need to know. *Thromb Haemostat*. 101: 279-283, 2009.
6. **Chong BH**, Chong JH. Heparin-induced thrombocytopenia. *Cardiovasc Therapy*, 2(4), 547-559, 2004.
7. **Chong BH**. Heparin-induced thrombocytopenia (State of Art Paper). *J Thromb Haemostat*. 1: 1471-8, 2003.
8. Ortel TL, **Chong BH**. New treatment options for heparin-induced thrombocytopenia. *Sem in Hematol* 35:4:5:26-34, 1998.
9. **Chong BH**, Eisbacher M. Pathophysiology and Laboratory Testing of Heparin-Induced Thrombocytopenia. *Sem in Haematol* 35:4:5:3-8, 199
10. Warkentin TE, **Chong BH**, Greinacher A.. Heparin-induced thrombocytopenia: review. *Thromb Haemostas* 79: 1-7, 1998.
11. **Chong BH**. Heparin-induced thrombocytopenia (Review). *Brit J Haematol* 1995; 89: 431-9.
12. **Chong BH**. Heparin-induced thrombocytopenia *Aust NZ J Med* 1992; 22:145-152
13. **Chong BH**, Berndt. MC. Heparin-induced thrombocytopenia (Leading Article) *Blut* 58:53-5, 1989.
14. **Chong BH**. Heparin-induced thrombocytopenia *Blood Review* 2:108-114, 1988

Peer-reviewed Journal Articles

15. K Boonyawat, P Angchaisuksiri, K Aryurachai, S Chaiyaroj, Z Ahmadi³, **BH Chong**. Low Prevalence of Heparin- induced Thrombocytopenia after Cardiac Surgery in Thai Patients. *Thromb Res*. Accepted 19th August 2014.
16. Savi P, **Chong BH**, Greinacher A, Gruel Y, Kelton JG, Warkentin TE, Eichler P, Meuleman D, Petitou M, Herault JP, Cariou R, Herbert JM. Effect of Fondaparinux on platelet activation in the presence of heparin-dependent antibodies: A blinded comparative multicentre study with unfractionated heparin. *Blood*, 105: 139-144, 2005.
17. **Chong BH**, Gallus AS, Cade J, Manoharan A, Magnani H, Chesterman CN. Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis. *Thromb Haemost*, 86: 1170-1175, 2001.
18. Newman P, **Chong BH**. Heparin-induced thrombocytopenia: New Evidence for the Dynamic Binding of Purified anti-PF4-heparin Antibodies to Platelets and the Resulting Activation. *Blood* 96: 182-187, 2000.

19. Newman P, **Chong BH**. Further characterization of antibody and antigen in heparin-induced thrombocytopenia. *Brit J Haematol* 107: 303-9, 1999.
20. Newman PM, Swanson RL, **Chong BH**. IgG Binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. *Thromb Haemostas* 80:292-297, 1998.
21. Vun CH, Evans S, **Chong BH**. Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia. *Thromb Res* 81:525-532, 1996.
22. Burgess JK, Lindeman R, Chesterman CN, **Chong BH**. Single amino acid mutation of Fcγ receptor predisposes to the development of heparin-induced thrombocytopenia. *Brit J Haematol* 91:761-766, 1995.
23. **Chong BH**, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. *Thromb Haemostas* 69:344-350, 1993.
24. **Chong BH**, Pilgrim RL, Cooley MA, Chesterman CN. Increased expression of platelet IgG Fc receptors in heparin induced thrombocytopenia. *Blood* 81:988-993, 1993.
25. **Chong BH**, Magnani HN. Organon in heparin-induced thrombocytopenia. *Haemostasis* 22:85-91, 1992.
26. **Chong BH**, Ismail F, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: Mechanism of interaction of the heparin-dependent antibody with platelets. *Brit J Haematol* 73:235-240, 1989.
27. **Chong BH**, Castaldi PA, Berndt MC. Heparin-induced thrombocytopenia: Effects of rabbit IgG and its Fab and Fc fragments on antibody-heparin-platelet interaction. *Thrombosis Research* 55:291-295, 1989.
28. **Chong BH**, Ismail F, Cade J, Gallus AS, Gordon S, Chesterman CN. Heparin-induced thrombocytopenia: Studies with a new low molecular weight heparinoid, Org 10-172. *Blood* 73:1592-1596, 1989.
29. **Chong BH**, Castaldi PA. Platelet pro-aggregating effect of heparin. Possible mechanism for non-immune heparin-induced thrombocytopenia. *Aust NZ J Med* 16:715-716, 1986.
30. **Chong BH**, Castaldi PA. Heparin-induced thrombocytopenia : Further studies of the effects of Heparin-dependent antibodies on platelets. *Brit J Haem* 64:347-354, 1986.
31. Sturges AD, **Chong BH**. Thrombotic thrombocytopenic purpura unresponsive to plasma infusion and plasma exchange, but responsive to splenectomy. *Scand J Haem* 37:319-322, 1986
32. **Chong BH**, Grace C, Rozenberg M, Castaldi PA. Platelet function defect in heparin-induced thrombocytopenia. *Scand J Haem* 30:427-429, 1983.
33. **Chong BH**, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia: Association of thrombotic complication with a heparin-dependent IgG antibody which induced platelet aggregation, release and thromboxane synthesis. *Lancet* ii: 1246-1248, 1982.
34. **Chong BH**, Grace CS, Rozenberg MC. Heparin-induced thrombocytopenia: Effects of heparin platelet antibody on platelets. *Brit J Haematol* 49:531-540, 1981.

Book Chapters.

35. Greinacher A, Warkentin TE, **Chong, BH**. Heparin-induced Thrombocytopenia, In *Platelets* (3rd Edition) Ed Michelson AD, Academic Press New York. 2012 pp 861-886.
36. **Chong, BH (2007)**. Heparin-induced Thrombocytopenia, In *Platelets* (2nd Edition) Ed Michelson AD, pp 861-886. Academic Press: New York.

37. **Chong BH**, Magnani HN. Danaparoid in the treatment of heparin-induced thrombocytopenia, in: Heparin-induced Thrombocytopenia, Eds: Warkentin T, Greinacher A 4th Edition. Marcel Dekker, New York, 2006.
38. **Chong BH**, Magnani HN. Danaparoid in the treatment of heparin-induced thrombocytopenia, in: Heparin-induced Thrombocytopenia, Eds: Warkentin T, Greinacher 3rd Edition. Marcel Dekker, New York, pp 371-396, 2004
39. **Chong, BH**. Magnani HN. Danaparoid in the treatment of heparin-induced thrombocytopenia, in: Heparin-induced Thrombocytopenia, Eds: Warkentin T, Greinacher A 2nd Edition. Marcel Dekker, New York, pp 323-347, 2002.
40. **Chong, BH**. Heparin-induced Thrombocytopenia, In *Platelets* (First Edition) Ed Michelson AD, Academic Press New York. Pp 571-591, **2002**.
41. **Chong BH**. Danaparoid in the treatment of heparin-induced thrombocytopenia, in: Heparin-induced Thrombocytopenia, Eds: Warkentin T, Greinacher A. 1st Edition. Marcel Dekker, New York, pp 291-311, 2000.
42. Magnani HN, Beijering RJR, ten Cate JW, **Chong BH**. Organ anticoagulation for Cardio- pulmonary by-pass in patients with heparin-induced thrombocytopenia, in: *New Anticoagulants for the cardiovascular patient*. Ed: R Pifarre. Henley and Belfus, Philadelphia, USA, pp 487-500, 1997.

Meeting posters or presentations (last 10 years)

43. **Chong BH**. Title of invited presentation: A new approach in the treatment of Heparin-induced thrombocytopenia. Congress of International Union of Angiology Meeting, Sydney, Australia, August 11th, 2014.
44. **Chong BH**. Title of invited presentation: A new approach in the management of HIT. Australasian Society of Thrombosis and Hemostasis /HHA Meeting, Sydney, Perth, Australia, 19th Oct, 2014.
45. Jaa Yien New, Jose Perdomo, Xing-Mai Jiang, and **Beng Chong**. Title of poster presentation: Heparin-Induced Thrombocytopenia and Thrombosis: Therapeutic Strategy Using a Single-Chain Variable Fragment (scFv) Antibody. Blood (ASH Annual Meeting Abstracts), Atlanta, Nov 2012; 120: 3346.
46. Jaa Yien New, Jose Perdomo, Xing-Mai Jiang and **Beng H Chong**. Title of poster presentation: Heparin-Induced Thrombocytopenia and Thrombosis - A New Emerging Therapeutic Strategy. Paper presented at XXIII Congress of the International Society of Thrombosis and Haemostasis, 2011, Japan
47. **Chong BH**. Title of invited presentation: Heparin-associated thrombocytopenia- current diagnosis and management. Pathology Update 2006. Scientific Update meeting of the Royal College of Pathologists of Australasian. 10th-12th March, 2006, Sydney, Australia.

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
National Health and Medical Research Council, Australia (Australian equivalent of NIH).	Studies of Novel Mechanisms, Diagnostic and Therapeutic Strategies for HIT.	Chief Investigator, research project	31 Dec 2014.

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I believe that I would receive strong support from them.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Primary clinical specialty: General Hematology; subspecialty: Thrombosis and Hemostasis.

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain:

I am a practicing clinical hematologist. From time to time I have patients with heparin-induced thrombocytopenia under my care. I would order diagnostic tests and prescribe treatment for my patients with heparin-induced thrombocytopenia.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

1. I have applied to National Health and Medical Research Council, Australia (Australian equivalent of NIH) for a research grant to study new mechanisms of HIT. Result of this application will be known in Oct 2015.
2. I may participate as a **site investigator** for the following clinical trials (starting dates - not known yet):
 - (a): A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic **ITP** (sponsor: Rigel);
 - (b) Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge **Venous Thrombo-Embolic** Risk (MARINER) (sponsor: Paraxel/Janssen).

If ASH deems that there is a problem with me participating these clinical trials I would transfer the role of site investigator to a colleague.

4/20/15 ASH Internal Note: The above clinical trials would not be considered a COI if Dr. Chong is a site investigator and all funding goes to his institution.

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Heparin Induced Thrombocytopenia (HIT)
----------------------------	---

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Reviewer Name and Date</i>	<i>Notes</i>
Yes	Unconflicted majority	No	04/21/2015' 04/27/2015	
Yes	Unconflicted majority	No	11/14/2016 Alexander; 11/14/2016 Rajasekhar	New interests disclosed. See Part D.
Yes	Unconflicted majority	No	7/31/2018 Alexander	New interests disclosed. See Part D. On 7/3/2018, Dr. Chong confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:

--

Part D. New Declarations

The following interests were disclosed after appointment:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Novartis	Direct payment for speaking on ITP at Malaysian Society of Hematology meeting (September 2016)	8/18/2016	No COI. Novartis does not market any drugs or devices used in the diagnosis or treatment of VTE.
Novartis	Direct payment for speaking on ITP at Hong Kong Society of Thrombosis and Haemostasis meeting (October 2016)	8/18/2016	No COI. Novartis does not market any drugs or devices used in the diagnosis or treatment of VTE.
Janssen-Cilag	Site investigator for Mariner Study (VTE prophylaxis in medical patients): no patients recruited. Involvement stopped 7/27/2017	7/3/2018	Not a COI. Janssen markets rivaroxaban. However, Dr. Chong does not have a leadership role and all funding goes to his institution.
Rigel	Site investigator for study on fostamatinib in ITP treatment (ended 2017)	7/3/2018	Not a COI. Rigel does not market any drugs or devices used in the diagnosis or treatment of VTE.
Bayer	Site investigator for Einstein Choice study on extended VTE treatment of rivaroxaban vs aspirin.	7/3/2018	Not a COI. Bayer markets rivaroxaban. However, Dr. Chong does not have a leadership role and all funding goes to his institution.
N/A	Chief investigator for study funded by the Medical Research Fund, Australia on VTE prophylaxis in patients undergoing hip or knee arthroplasty: aspirin	7/3/2018	Not a COI. The Medical Research Fund is an initiative supported by the Australian Department of Health, and does not market any drugs or devices

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	vs enoxaparin (ended June 2020)		used in the diagnosis or treatment of VTE.



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Syntonix	Consultant	4/2015	Ended before panel appointment. The company is also unaffected by guidelines on HIT. It has hemophilia products and is a subsidiary of Biogen, which has products for MS, hemophilia, and cancers.
Bayer	Consultant	4/2014	Ended before panel appointment
Instrument Labs	Consultant	10/2014	Ended before panel appointment
Amgen	Consultant	12/2014	Ended before panel appointment
GSK	DSMB	4/2015	GSK markets the anticoagulants fondaparinux and

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
			argatroban. This activity ended before panel appointment and will be paid at the end of June 2015. Dr. Cines' appointment and work on the guideline panel will not begin until after payment is made.
True North	Consultant	12/2014	Ended before panel appointment
Sanofi	Consultant	2/2014	Ended before panel appointment

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
T2 Biosystems	Develop clotting assay	PI	05/2016	Not a conflict because although T2 Biosystems markets blood testing products, it does not market a specific test for HIT.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Heparin-Induced Thrombocytopenia

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Summarized in article requested by Blood entitled "How I treat HIT".

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
NIH	Pathogenesis of HIT	PI	ongoing

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I don't foresee any problems.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Hematology

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain:

I consult on patients with HIT and I am director of a coagulation laboratory in which these tests are performed

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Heparin-Induced Thrombocytopenia
----------------------------	---

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Reviewer name and date</i>	<i>Notes</i>
Yes	Unconflicted majority	No	4/10/15; 4/25/15	Dr. Cines is the PI on research funded by T2 Biosystems, but this is not an affected company. He has past income from speaking and consulting. To remain in the unconflicted majority, he must agree to avoid new interests in affected companies during guideline development.
Yes	Conflicted minority	Yes	10/14/15; 10/15/15	Status changed. New financial interests disclosed. See Part D.
Yes	Conflicted minority	Yes	8/31/16; 9/16/16 Rajasekhar	New financial interests disclosed. See Part D.
Yes	Conflicted minority	Yes	10/12/2016 Alexander; 10/21/16 Kunkle	New interest disclosed. See Part D.
Yes	Conflicted minority	Yes	8/11/2017 Alexander	New interest disclosed. See Part D. Dr. Cines disclosed a relationship with Sanofi Aventis, which markets enoxaparin, after the panel formed recommendations at the November 2016 meeting. Therefore, this relationship did not trigger recusal. However,

				Dr. Cines was already recused for all applicable questions due to his relationships with other companies (summarized below).
Yes	Conflicted minority	Yes	6/26/2018 Alexander	New interests disclosed. See Part D. On 6/27/2018 Dr. Cines confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Bayer	Personal income for serving on an advisory board	10/9/2015	Bayer markets rivaroxaban.
Momenta Pharma	Personal income for serving on a medical advisory board	10/9/2015	Momenta markets enoxaparin.
Sanofi Aventis	Dr. Cines is the PI of a study on heparin induced thrombocytopenia	8/3/2017	Sanofi markets enoxaparin, Dr. Cines has a leadership role, and the subject of the research is related to the guideline topic.
CSL Behring	Personal income for consulting	6/27/2018	CSL Behring markets Kcentra, a warfarin reversal agent.

Notes:

--

Part D. New Interests

The following interests were disclosed after appointment:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Rigel	DSMB	10/9/2015	Not a COI. Not an affected company.
Bayer	Med Ad Board	10/9/2015	COI. Bayer markets rivaroxaban.
Novartis	Med Ad Board	10/9/2015	Not a COI. Not an affected company.
Syntimmune	Med Ad Board	10/9/2015	Not a COI. Not an affected company.
Momenta Pharma	Med Ad Board	10/9/2015	COI. Momenta markets enoxaparin.
Ionis	Advisory Board	8/31/2016	Not a COI. Not an affected company.
Amgen	Advisory Board	8/31/2016	Not a COI. Not an affected company.
Syntimmune	Dr. Cines is the PI of a study researching tissue factor production by IgG receptors.	09/20/2016	Not a COI. Not an affected company. Furthermore, the research is unrelated to the guideline topic.
Sanofi Aventis	Dr. Cines is the PI of a study on heparin induced thrombocytopenia	8/3/2017	COI. Sanofi markets enoxaparin, Dr. Cines has a leadership role, and the subject of the research is related to the guideline topic.
CSL Behring	Consulting	6/27/2018	COI. CSL Behring markets Kcentra, a warfarin reversal agent.
Various	Dr. Cines no longer receives payments/funding from Bayer, Rigel, Novartis, Momenta, Ionis, Amgen or Sanofi.	6/27/2018	Not a COI. This is an update to previous disclosures.



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
CSL Behring	Advisory Board	1/25/14	Disclosed 10/22/14. Ended before appointment to Guideline Coordination Panel or HIT panel.
Bracco Diagnostics	Consultancy	12/31/14	Disclosed 10/22/14. Ended before appointment to HIT panel.
Genzyme	Consultancy	Ongoing	Disclosed 10/22/14. This company has no products for HIT or VTE and would not be affected by guidelines on these topics. Genzyme is a subsidiary of Sanofi; however, Dr. Cuker has no direct financial relationship with Sanofi.

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Stago	Research Funding	Investigator	12/31/2014	Disclosed 10/22/2014. Stago makes an apixaban anti-Xa assay so could be affected by guidelines that address this product or apixaban. However, Dr. Cuker does not have a leadership role in this research, and he previously confirmed that all funding goes to his institution.
T2 Biosystems	Research Funding	Investigator	Ongoing	Disclosed 10/22/2014. T2 Biosystems markets blood testing products. Dr. Cuker does not have a leadership role in this research, and he previously confirmed that all funding goes to his institution.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Topic	Guideline Panel Name
Venous thromboembolism (VTE)	VTE Guideline Coordination Panel
Treatment of acute VTE (deep vein thrombosis and pulmonary embolism)	Guideline Panel on Treatment of Acute VTE
Heparin-induced thrombocytopenia (HIT)	Guideline Panel on HIT

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes (Disclosed 12/7/2014)

If yes, what were those views and where were they made?

1. Diagnosis of HIT using the 4T score (Blood 2012; 120:4160)
2. Treatment of HIT (Blood 2012; 119:2209)

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
NIH/NHLBI	Improving the diagnosis of HIT	Principal investigator	7/30/15

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain: I believe that my institution and its reputation benefit when I write or speak on VTE under the imprimatur of the institution.

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

My institution and mentor would be pleased to the extent that I participated in development and publication of high-impact guidelines. (Disclosed 12/7/2014)

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Adult hematology, special interest in thrombosis and hemostasis (Disclosed 12/7/2014)

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes (Disclosed 12/7/2014)

If yes, please explain: I diagnose and manage patients with VTE.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	VTE Guideline Coordination Panel; Guideline Panel on Heparin-Induced Thrombocytopenia; Guideline Panel on Treatment of Acute VTE
----------------------------	--

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Reviewer Name and Date</i>	<i>Notes</i>
Yes	Unconflicted majority	No	4/7/2015; 4/24/15	Dr. Cuker has no current material interests in companies potentially affected by ASH VTE guidelines and has agreed to avoid such interests during guideline development.
Yes	Unconflicted majority	No	9/15/15; 10/15/15	New financial interest disclosed. See Part D.
Yes	Unconflicted majority	No	11/13/15; 11/15/15	New research interest disclosed. See Part D.
Yes	Unconflicted majority	No	3/18/16 Panepinto and Rajasekhar	New financial interest disclosed. See Part D.
Yes	Unconflicted majority	No	5/24/18 Alexander	New interest disclosed. See Part D.
Yes	Unconflicted majority	No	7/31/18 Alexander	On 6/22/2018, Dr. Cuker confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:

--

Part D. New Declarations

The following interests were disclosed after appointment:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Amgen	One-time consulting	9/9/15	No COI. Amgen does not market any products related to VTE.
Spark	I will serve as Site-PI for a clinical trial of gene therapy for hemophilia B sponsored by Spark Therapeutics (Gold-B trial). I will receive salary support for this role.	11/13/15	No COI. Spark does not market any products related to VTE.
Biogen-Idec	I have been asked to give a talk on hemophilia at a symposium supported by Biogen-Idec. I will have control over the slides. It is CME and the payment will come through an education company.	3/16/16	No COI. Biogen-Idec does not market any products related to VTE.
Expert Perspectives	Payment for written content about treatment of ITP	5/24/2018	Not a COI. Expert Perspectives does not market any products used in the treatment or diagnosis of VTE. By email, he said that Expert Perspectives confirmed that they do not receive any funding pharmaceutical companies.



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>
One Lambda	Patent on the HNA-3a antigen relevant in transfusion medicine	2011	Divested before appointment

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Boehringer Ingelheim	Consultant for development of idarucizumab Coverage of travel costs All consultant fees are going to the university	ongoing	Boehringer markets dabigatran. However, this is not a direct relationship: all fees go to his institution.
Bristol Myers Squibb	Non restricted grant for the educational activity	ongoing	COI: BMS markets apixaban.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
	Thrombosis Expert Academy		
MacoPharma	Consultant on the development of pathogen in activation of platelet concentrates	ongoing	MacoPharma markets transfusion products. Not an affected company.
MSD	Medical advice for the use of danaparoid in complicated HIT cases	2014	MSD markets danaparoid. However, this interest ended before appointment.
ASPEN	Medical advice for the use of danaparoid in complicated HIT cases	ongoing	COI: Aspen markets danaparoid.
Instrumentation Laboratory	Advisory board	ongoing	COI: Instrumentation Laboratory markets technologies for whole blood and hemostasis testing. They have an assay specific for HIT.
Chromatec	Advisor on PF4 production	ongoing	COI: ChromaTec offers PF4 antigen for HIT antibody test.

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Sagent Ltd	Assessment of low molecular weight heparin with PF4 and HIT antibodies	PI	ongoing	COI: Sagent Ltd manufactures heparin sodium injections.
Prosensa	Assessment of aptamers with PF4 and HIT antibodies	PI and consultant	ongoing	Not an affected company

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Heparin-Induced Thrombocytopenia

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain: I am working since 27 years on the topic

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made? ~300 publications plus guidelines plus text book articles. Cannot list all this here.

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
BMBF (German Ministry of Education and Research)	Antibody mediated cardiovascular disease	investigator	12-2014
Deutsche Forschungsgemeinschaft	Pathogenesis of HIT	Investigator and coinvestigator	ongoing

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain: Being a member of advisory boards I have early access to information

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I have the privilege of a German government employee position which legally guarantees full protection and freedom of my research.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?
Transfusion Medicine, Subspecialty Hemostasis

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain: Diagnosis of HIT and treatment of HIT

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Heparin-Induced Thrombocytopenia
----------------------------	---

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Date reviewed by ASH staff</i>	<i>Notes</i>
Yes	Conflicted minority	Yes	4/8/2015; 4/24/2018	
Yes	Conflicted minority	Yes	6/28/2018 Alexander	Updates to disclosures. See Part D. On 6/29/2018, Dr. Greinacher confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Bristol Myers Squibb	Personal income or other remuneration: Nonrestricted grant for the educational activity Thrombosis Expert Academy	04/08/2015	BMS markets apixaban.
ASPEN PharmaCare	Personal income or other remuneration: Medical advice for the use of danaparoid in complicated HIT cases	04/08/2015	Aspen markets danaparoid.
Instrumentation Laboratory	Personal income or other remuneration: Advisory board	04/08/2015	Instrumentation Laboratory markets technologies for whole blood and hemostasis testing. They have an assay specific for HIT.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Chromatec	Personal income or other remuneration: Advisor on PF4 production	04/08/2015	ChromaTec offers PF4 antigen for HIT antibody test.
Sagent Ltd	PI on research funded by Sagent re assessment of low molecular weight heparin with PF4 and HIT antibodies	04/08/2015	Sagent Ltd manufactures heparin sodium injections

Notes:

--

Part D. New Interests

The following interests were disclosed after appointment:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Bristol Myers Squibb	Non restricted grant for the educational activity Thrombosis Expert Academy. This activity ended in 2017	6/29/2018	This is an update to Part A, Question 3.
Boehringer Ingelheim	Consultant for development of idarucizumab Coverage of travel costs All consultant fees are going to the university. This activity ended in June 2018	6/29/2018	This is an update to Part A, Question 3.



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Sanofi	Speaker honoraria (on heparins and cancer). I will participate with SANOFI next June to a meeting on the use of anticoagulants in cancer patients and will be paid (500 € taxes included) just after. I don't have any other project with this company, so far.	July 2015	No COI. Sanofi makes enoxaparin (a LMWH). Although heparins are contraindicated for patients with HIT, the guidelines could make recommendations about using heparin in some circumstances when benefits outweigh risks. However, Dr. Gruel confirmed via email on 5/15/15 that he will refuse payment for this activity.
Sobi	Advisory Board member (on the use of long lasting FVIII).	Ongoing	No COI. Sobi makes argatroban, a reversible direct thrombin inhibitor indicated for anticoagulation in adult

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
			patients who have developed HIT type II. However, Dr. Gruel confirmed by email that he does not receive any income from this activity. All income goes to his institution.
LFB	Speaker honoraria (presentation about HIT)	2014	Ended before appointment
Stago	Speaker honoraria	2014	Ended before appointment
Roche	Advisory Board member for POC PT measurement	2014	Ended before appointment
Pfizer	Travel support for meeting	2014	Ended before appointment
Léo	Advisory Board member (Cancer and Thrombosis)	Ongoing	No COI: Leo Pharma makes enoxaparin (a LMWH). Although heparins are contraindicated for patients with HIT, the guidelines could make recommendations about using heparin in some circumstances when benefits outweigh risks. However, Dr. Gruel confirmed via email on 5/15/15 that he will refuse payment or discontinue this activity.
CSL Behring	Speaker honoraria (on the treatment of Hemophilia) and Travel	2014	Ended before appointment

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
	support for ASH meeting		
Novo	Air Travel support for EHAD meeting (Hemophilia) in Helsinki	2015	Novo Nordisk markets novoseven, used off label to reverse anticoagulation. However, the EHAD meeting (Feb 2015) occurred before appointment.

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Stago	Support and funding for the evaluation of a rapid assay for the diagnosis of HIT (Article in Brit J Haematol, 2014)	Co-investigator	2014	Ended before appointment
BioGen	BioGen, has asked me to be a member of a working group in France on the use of FVIII-Fc in hemophilia, with two meetings planned next July and December (payment few weeks later), but this activity is completely unrelated to HIT.	PI	December 2015	Not an affected company

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Stago	Support and funding for the evaluation of a rapid assay for the diagnosis of HIT (Article in Brit J Haematol,	2014	See above; ended before appointment

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
	2014) Co-investigator (Claire Pouplard)		

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Heparin-Induced Thrombocytopenia

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

I believe on the necessity a/ to perform sensitive and specific biological assays in any patient with suspected HIT and b/ to prescribe an alternative efficient no-heparin treatment in case of clinical suspicion.

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Last year, I published a review (in French) (Gruel Y, Rollin J, Leroux D, Pouplard C. Heparin-induced thrombocytopenia: recent data. Rev Med Interne. 2014 Mar; 35(3):174-82.), about the current knowledge on the pathogenesis, the diagnosis (with a clinico-biological approach) and the treatment of HIT, and discussing the use of drugs that have been approved in France in this clinical setting.

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
 Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
 No
 Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

- Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I don't think that my participation to these guidelines will have any impact on my career, since I am a full professor in my University since 1993 and I obtained the highest rank in this position a year ago. In addition, I'm not sure to have well understood what you meant by "strong reaction from peers outside your institution" but I think that in case of unexpected "trouble" resulting from this work, I should be fully supported by my institution.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Hematology-Hemostasis

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain: Since I am identified as an expert in this field in France I am regularly joined for discussing about patients with suspected HIT, about the diagnosis of this complication and its management.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Heparin-Induced Thrombocytopenia
----------------------------	----------------------------------

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Date reviewed by ASH staff</i>	<i>Notes</i>
Yes	Unconflicted majority	No	4/13/2015 ; 4/25/2015	Dr. Gruel has relationships with affected companies, but he has agreed to refuse payment from or discontinue his activities with Sanofi and Leo Pharma.
Yes	Unconflicted majority	No	10/6/2016	New disclosure. See Part D.
Yes	Unconflicted majority	NO	8/24/2018	New disclosures. See Part D. On 8/24/2018, Dr. Gruel confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:

--

Part D. New Declarations

The following interests were disclosed after appointment:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Stago	We developed in my lab in 2013 with Jérôme Rollin and Claire Pouplard, in collaboration with a company named B Cell Design, a chimeric monoclonal antibody named 5B9 that has a human Fc fragment, and which perfectly mimics human HIT antibodies in terms of specificity and ability to activate cells. This antibody was developed for research purpose, but the clone was purchased few months ago in the first trimester of 2016 by STAGO, a French company involved in the development of assays for in vitro Diagnosis. The contract was established between my University, the CNRS, B Cell Design and STAGO, and none of us (Claire Pouplard, Jérôme Rollin and me) received and will receive in the future any financial benefit following this contract.	10/5/2016	Not a COI. Dr. Gruel did not receive any payment from the sale of the antibody and will not receive any payments in the future. All payments from the contract went to B Cell Design and his institution.
Aspen	Direct payment for speaking in May 2017	8/24/2018	Not a COI. Aspen markets enoxaparin sodium, however this

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
			activity occurred after the November 15-16, 2016 meeting, when all recommendations regarding heparin were finalized.
LFB	Direct payment for expert testimony on argatroban in HIT in 2018.	8/24/2018	Not a COI. This activity occurred after all recommendations were finalized



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Bayer Inc	Lecture honoraria	Nov 7, 2014	Ended before appointment
Pfizer Canada	Ad board meeting chair	Mar 11, 2015	Ended before appointment

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Bayer Inc	Investigator-sponsored study evaluating rivaroxaban as treatment for suspected or confirmed HIT	PI	Feb 2016	COI: Bayer is an affected company (rivaroxaban), the subject of the research is HIT, and Dr. Linkins has a PI role in this research.

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Heparin-Induced Thrombocytopenia

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

I was Chapter Editor and first author for the Treatment and Prevention of Heparin-Induced Thrombocytopenia: ACCP evidence-based clinical practice guideline (9th edition) and have both published and presented on diagnosis and treatment of HIT.

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
 Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
 No
 Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

- Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

No concerns.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Thrombosis consultant

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain: I diagnose and treat patients with suspected and confirmed HIT as part of my routine clinical practice.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Heparin-Induced Thrombocytopenia
----------------------------	---

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Date reviewed by ASH staff</i>	<i>Notes</i>
Yes	Conflicted minority	Yes	4/14/15; 4/25/15	
Yes	Conflicted minority	Yes	10/13/16 Alexander; 10/18/16 Kunkle	New disclosures. See Part D.
Yes	Conflicted minority	Yes	6/28/2018 Alexander	On 6/25/2018, Dr. Linkins confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Bayer	Principal investigator for a Bayer-funded study evaluating rivaroxaban as treatment for suspected or confirmed HIT	4/09/15	Bayer markets rivaroxaban, the subject is HIT, and Dr. Linkins has a leadership role.
Bayer	Direct payment for data adjudication for the MARINER study, a DVT prophylaxis study of placebo vs. rivaroxaban for medical patients	9/23/16	Bayer markets rivaroxaban.

Notes:

--

Part D. New Declarations

The following interests were disclosed after appointment:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Bayer	Direct payment for Data Adjudication for the MARINER study (DVT prophylaxis study for medical patients: placebo vs rivaroxaban)	9/23/16	COI. Bayer markets rivaroxaban.
Bayer	Principal investigator for a Bayer-funded study evaluating rivaroxaban as treatment for suspected or confirmed HIT. This previously reported activity ended in June 2016.	9/23/16	This activity remains a COI. Bayer markets rivaroxaban, and the activity occurred during the guideline development process.



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Heparin-Induced Thrombocytopenia

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

I am on the Board Of The National Blood Clot Alliance and I feel strongly about supporting public awareness of VTE and reducing hospital acquired VTE

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

- Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I'm sure I would receive support from NBCA. My employer is a law firm and not applicable.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

I am not in healthcare.

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Heparin-Induced Thrombocytopenia
----------------------------	---

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Review Name and Date</i>	<i>Notes</i>
Yes	Unconflicted majority	No	8/13/15; 8/16/15	
Yes	Unconflicted majority	No	6/28/2018 Alexander	On 6/25/2018, Mr. Rodner confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Heparin-Induced Thrombocytopenia

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Does not apply.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Does not apply.

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Heparin-Induced Thrombocytopenia
----------------------------	---

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Date reviewed by ASH staff</i>	<i>Date confirmed by ASH oversight officer or committee</i>	<i>Notes</i>
Yes	Unconflicted majority	No	8/13/15	8/16/15	
[Add rows as new interests are disclosed and reviewed.]					

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:

--



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Heparin-Induced Thrombocytopenia
VTE in the Context of Pregnancy

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I believe that these entities would support my methodological expertise and decisions.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

I am a registered dietitian in Canada with no particular specialty.

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Heparin-Induced Thrombocytopenia VTE in the Context of Pregnancy
----------------------------	---

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Reviewer Name and Date</i>	<i>Notes</i>
Yes	Unconflicted majority	No	05/08/2015; 05/09/2015	
Yes	Unconflicted majority	No	7/2/2018 Alexander	On 6/22/2018, Dr. Santesso confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Heparin-Induced Thrombocytopenia

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Heparin-induced thrombocytopenia is still overdiagnosed mainly because laboratories that perform the antibody tests don't know much enough about the clinical picture of the individual patient, and clinicians often have problems to interpret the laboratory test result. A better cooperation between the laboratory and the clinical staff would be helpful.

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

I am an author or co-author, respectively, of two letters directed to the American Heart Journal (Selleng S, Greinacher A, Ittermann T, Wollert HG. Heparin/PF4 antibodies formation after heparin treatment: temporal aspects and long-term follow-up. *Am Heart J.* 2009; **158**: e15.) and to the Annals of Thoracic Surgery (Pappalardo F, Greinacher A, Selleng S. Postoperative complications after cardiac surgery and HIT: a word of caution. *Ann Thorac Surg.* 2008; **86**: 1054-5).

In the first, we have responded to an article in this journal and disagreed with the conclusion of this article that anti-/platelet factor 4 antibodies per se are associated with thromboembolic complications and that cardiovascular patients should therefore be screened for these antibodies. In the other letter we have expressed our doubts that anti-/platelet factor 4 antibodies really indicate a worse post cardiac surgery outcome.

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

X No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I can't imagine that this work could change any conditions of my relations to my primary mentor, to my institution (University Medicine in Greifswald), or other entities.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

X No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

I've been an anesthetist for over 20 years who currently works as intensivist at a 25-bed intensive care unit of the University Medicine-hospital of Greifswald.

I have worked together with Professor Greinacher between 2006 and 2010 at the Department of Transfusion Medicine of our hospital. There I have learned the most about heparin-induced thrombocytopenia.

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Heparin-Induced Thrombocytopenia
----------------------------	---

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Date reviewed by ASH staff</i>	<i>Notes</i>
Yes	Unconflicted majority	No	08/13/15; 8/16/15	
Yes	Unconflicted majority	No	6/28/2018 Alexander	On 6/25/2018, Dr. Selleng confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:

--



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>
Taylor & Francis (Informa)	Royalties for co-editing textbook, "Heparin-Induced Thrombocytopenia", published 2013 by CRC Press, Boca Raton, FL (part of Taylor & Francis [Informal])	ongoing	OK. Publishers do not meet our definition of "companies" potentially affected by the guidelines.

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Pfizer Canada	Lecture honoraria	Ongoing	COI: Pfizer markets apixaban and dalteparin (a LMWH).
Instrumentation Laboratory (IL)	Advisory board; lecture honoraria	Ongoing	COI: Instrumentation Laboratory makes technologies for whole blood and hemostasis testing. They have an assay specific for HIT.
W.L. Gore	Consulting	Ongoing	W.L. Gore makes heparin-coated grafts. However, the guidelines are unlikely to address use of grafts. So Gore is unlikely to be affected.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Legal firms	Expert testimony	Ongoing	Not an affected company

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
W.L. Gore	Anti-PF4/heparin antibody formation in association with use of heparin-coated vascular grafts	Responsible for laboratory studies	2-3 years from now (?)	W.L. Gore makes heparin-coated grafts. However, the guidelines are unlikely to address use of grafts. So Gore is unlikely to be affected by guidelines that recommend against the use of heparin-coated grafts.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Heparin-Induced Thrombocytopenia

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain: I have chaired previous consensus conference guidelines (e.g., ACCP, 2004; ACCP 2008) and presumably would have "beliefs" that the views expressed therein were likely to be reasonable. That said, my views would be expected to evolve with new information identified as part of new guidelines development.

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Too many to articulate-- see curriculum vitae (can be provided on request); can provide any listed individual articles or book chapters on request.

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
None	Clinical and laboratory aspects of HIT, e.g., timing of onset of thrombocytopenia post-cardiac surgery, risk factors for post-heparin bolus anaphylactoid reactions, timing and magnitude of antibody formation in relation to development of HIT, frequency and nature of DIC complicating HIT, subtypes of anti-PF4/heparin antibodies, etc.	Principal and/or associate investigator	Ongoing

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain: I see patients with HIT (and my institution receives revenues related to my clinical consultations); I sometimes discuss patient cases with physicians outside my institution (which might lead to them referring blood samples to my institution for laboratory testing); my

institution (university) receives "overhead" fees for contracted research (e.g., W.L. Gore-funded research project, described above).

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I would anticipate no problems from my mentor/institution, etc.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes [Warkentin TE, Greinacher A, Gruel Y, Aster RH, Chong BH; Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. *J Thromb Haemost* 2011 Dec; 9 (12): 2498-2500. Epub 2011 Oct 15.]

If yes, are you involved in formulating or voting for positions?

No (at least, not going forward)

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Clinical and laboratory hematology

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain:

I routinely recommend diagnostic tests and treatments for HIT in my practice, consulting, writing, lecturing, etc.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

Don't know

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Heparin-Induced Thrombocytopenia
----------------------------	---

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Reviewer Name and Date</i>	<i>Notes</i>
Yes	Conflicted minority	Yes	04/21/2015; 4/25/2015	
Yes	Conflicted minority	Yes	8/4/2016; 8/5/16 Rajasekhar	New disclosures, including new financial COI. See Part D.
Yes	Conflicted minority	Yes	7/31/2018 Alexander	Update to disclosures. See Part D. On 7/2/2018, Dr. Warkentin confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Pfizer Canada	Personal income from speaking	04/14/2015	Pfizer markets apixaban and dalteparin (a LMWH).
Instrumentation Laboratory	Personal income from service on an advisory board and from speaking	04/14/2015	Instrumentation Laboratory makes technologies for whole blood and hemostasis testing. They have an assay specific for HIT.
Instrumentation Laboratory	Principal investigator for research testing well-characterized sera & plasmas from heparin-exposed patients using their instruments (ACL TOP; AcuStar) and HIT assays.	8/3/2016	Instrumentation Laboratory makes technologies for whole blood and hemostasis testing. They have an assay specific for HIT.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
W.L. Gore	Research funding	04/14/2015	Potential COI with W.L. Gore if guidelines address heparin-coated grafts.
Aspen	Personal income for consulting	8/3/2016	Aspen markets danaparoid and fondaparinux.
Stago	Personal income for writing a chapter for a monograph	8/3/2016	Stago markets coagulation tests, including an anti-Xa assay.

Notes:

--

Part D. New Declarations

The following interests were disclosed after appointment:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Pfizer Canada	Personal income for speaking. This previously reported activity ended October 2014.	8/3/16	COI. Under ASH policy, past financial relationships are not generally considered a COI. However, before appointment to the guideline panel, Dr. Warkentin described this activity as “ongoing” (see p. 2), suggesting that he expected possible continued payments for speaking during the guideline development process. It therefore seems reasonable and conservative to continue to judge this ended activity to be a relevant COI. This judgment will have no impact on Dr. Warkentin’s status or required recusal from recommendations about anticoagulants because of his new disclosure below that he is doing paid consulting for Aspen.
Medtronic Diabetes	Personal income for consulting. This company has no direct role in HIT, but they are performing a study in which patients are exposed to heparin, and they requested	8/3/16	Not a COI. Medtronic markets a variety of medical devices, including vascular compression stockings for VTE, but these products are outside scope of guidelines on HIT.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	advice on HIT-related issues.		
Aspen Global Inc.	Personal income for consulting	8/3/16	COI. Aspen markets danaparoid and fondaparinux.
Stago	Personal income for writing a chapter about danaparoid for a monograph entitled "Parenteral Anticoagulants." Ended July 2016.	8/3/16	COI. Stago markets coagulation tests, including an anti-Xa assay.
Instrumentation Laboratory	Principal investigator for research testing well-characterized sera & plasmas from heparin-exposed patients using their instruments (ACL TOP; AcuStar) and HIT assays. All funding to institution.	8/3/16	COI. Instrumentation Laboratory markets an assay specific for HIT. Although all funding goes to his institution, Dr. Warkentin has a leadership role in this research.
Pfizer Canada	Lecture honoraria. This activity has ended, Dr. Warkentin's last lecture for Pfizer Canada was in 2014.	7/3/2018	This is an update to Part A, Question 3.